Ascendis Pharma A/S
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BioMarin and Ascendis Pharma settled a patent dispute, with Ascendis agreeing to pay BioMarin royalties. The dispute involved treatments for a genetic disorder. The agreement ends legal proceedings between the two companies.
Ascendis Pharma (ASND) and BioMarin Pharmaceutical settled patent disputes over Yuviwel and navepegritide-related products. The deal grants Ascendis a worldwide license to develop and commercialize navepegritide therapies, ending litigation and providing commercial clarity. This removes legal risks and replaces them with royalty obligations on Yuviwel sales until 2030, potentially benefiting Ascendis' rare disease portfolio and investor risk assessments.
U.S. stocks fell midday, with the Dow, Nasdaq, and S&P 500 down 0.64%, 0.40%, and 0.51% respectively. Energy shares rose 1.8%, while communication services dropped 1.9%. The Dallas Fed's manufacturing index surged to 11.6 in August. Notable movers: CLGN (+123%), ASND (+6%), TITN (+13%), FNGR (-39%), EIX (-23%), PCG (-20%). Oil gained 2.5% to $85.50, while gold fell 1.3% to $4,473.10. European and Asian markets were mixed.
Over the past 7 days, alphai's AI scored 11 news stories mentioning ASND (Ascendis Pharma A/S). Coverage has skewed bullish: 4 bullish, 5 neutral, and 2 bearish.
Recent ASND coverage spans financial news, corporate actions and market movers.
In the last 30 days, ASND insiders filed 2 SEC Form 4 transactions — 2 purchases ($493K) and no sales. The most active reporter was BIENAIME JEAN JACQUES with 2 filings.
Future royalty expense for Ascendis.
The settlement removes legal risk and introduces a royalty expense, likely reducing volatility and improving long-term valuation.
Resolution of patent litigation removes a major risk.
Positive price reaction to licensing deal.
Royalty expense will reduce margins but removes litigation risk.
alphai scores every news story that mentions ASND with an AI model for sentiment and relevance, and aggregates insider trades from Ascendis Pharma A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioMarin and Ascendis Pharma settled a patent dispute, with Ascendis agreeing to pay BioMarin royalties. The dispute involved treatments for a genetic disorder. The agreement ends legal proceedings between the two companies.
1 min readAscendis Pharma (ASND) and BioMarin Pharmaceutical settled patent disputes over Yuviwel and navepegritide-related products. The deal grants Ascendis a worldwide license to develop and commercialize navepegritide therapies, ending litigation and providing commercial clarity. This removes legal risks and replaces them with royalty obligations on Yuviwel sales until 2030, potentially benefiting Ascendis' rare disease portfolio and investor risk assessments.
2 min readU.S. stocks fell midday, with the Dow, Nasdaq, and S&P 500 down 0.64%, 0.40%, and 0.51% respectively. Energy shares rose 1.8%, while communication services dropped 1.9%. The Dallas Fed's manufacturing index surged to 11.6 in August. Notable movers: CLGN (+123%), ASND (+6%), TITN (+13%), FNGR (-39%), EIX (-23%), PCG (-20%). Oil gained 2.5% to $85.50, while gold fell 1.3% to $4,473.10. European and Asian markets were mixed.
2 min readAscendis Pharma (ASND) shares rose 6% after signing a global settlement and license agreement with BioMarin Pharmaceutical. The stock traded at $263.10, up from $247.65, with a 52-week range of $186.05 to $282.15.
1 min readBiomarin and Ascendis Pharma settled a patent dispute over achondroplasia drugs. Biomarin will receive 18–20% royalties on Yuviwel sales until 2030. Analysts view the agreement as favorable for both companies, with Ascendis gaining market access and Biomarin securing high royalties.
3 min readAscendis Pharma (ASND) has agreed to pay BioMarin 20% of U.S. net sales and 18% in the EU, South Korea, and Brazil for YUVIWEL (navepegritide) through 2030. The deal resolves all litigation and grants Ascendis a non-exclusive, worldwide license. Ascendis expects over €500M in operating cash flow by 2026 and €5B in revenue by 2030, with FDA approval for YUVIWEL anticipated in February 2026.
2 min readAscendis Pharma (ASND) presented 2-year data on TransCon CNP for achondroplasia, showing durable outcomes and a consistent safety profile. The company also announced FDA approval of YUVIWEL for pediatric achondroplasia, a key milestone in its rare disease portfolio.
3 min readHC Wainwright initiated coverage on Ascendis Pharma (ASND) with a Buy rating and $345 price target. Truist Securities initiated DigitalOcean (DOCN) with a Buy rating and $175 target. HC Wainwright also initiated Odyssey Therapeutics (ODTX) with a Buy rating and $44 target.
1 min readAscendis Pharma (ASND) reported Q2 2026 revenue of EUR 339M, up 100% YoY, driven by YORVIPATH (EUR 252M) and YUVIWEL's U.S. launch. Operating profit was EUR 220M, boosted by a EUR 158M PRV sale. Management guided to EUR 500M+ operating cash flow for 2026 and EUR 5B revenue by 2030, but noted rising expenses and legal risks.
3 min readAscendis Pharma will present 104-week data from its pivotal trial of TransCon CNP (Navepegritide) at the International Society for Pediatric and Adolescent Diabetes (ISDS) 2026 conference. The presentation will showcase long-term results of the drug's efficacy and safety in treating a specific medical condition.
1 min read
